News
FDA Scrutiny of Novavax COVID Shot Sparks Uncertainty About Other Vaccines
The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional protein-based option for the coronavirus -- is sowing uncertainty about updates to other vaccines too.
There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback